Compared to ccRCC (Fig. 2) BAP1, CHEK2, IRS1, PBRM1, SETD2, TERT, and VHL in evRCC patients, PAX8, CDKN2A, CDKN2B, FANCC, FGFR4, PIK3C, PTPRS, SMARCB1, TERT in pRCC ASXL2, BRCA1, CDH1, CDKN2A, CDKN2B, CDKN2C, DNMT1, and EP300 mutations in chRCC patients were mainly found. This evidence concerns the gene ASXL2 and nonpapillary renal cell carcinoma.